Please login to the form below

Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Anne Legendre reviews the scientific rationale behind immunotherapy combinations and Frances Hendry examines how partnerships, co-marketing and positioning drugs will play key roles in shaping the competitive landscape in oncology.
With the promise of using the body’s own immune system to fight cancer, immunotherapy has received significant interest from the scientific community, bringing hope to patients across many cancer indications.

The recent development of immunotherapies has led to considerable change in the oncology treatment landscape, driving transformation in the standard of care and yielding lasting responses in patients with metastatic cancers.
While promising, first and second generations of agents have demonstrable weaknesses too, such as:
  • Reduced efficacy in a limited subset of patients
  • Increased resistance mechanism, where patients do not respond or stop responding
  • Toxicity issues, which diminish quality of life for patients.
In order to optimise agent efficacy and overall patient survival, most of these agents are now used in combination. This shift has led to a proliferation of combination studies and approvals, as well as research and commercial partnerships between top pharma companies and small biotechnology companies with innovative product pipelines.

What are the immunotherapy agents currently investigated in monotherapy and in combination?

The first generation of agents has shown some interesting results, while also highlighting the limits of immunotherapies in oncology.

Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.

The second wave of agents encompasses checkpoint inhibitors and cell therapies, among others. Nivolumab, pembrolizumab and atezolizumab are checkpoint inhibitors, meaning that they help the immune system to recognise and kill tumour cells. These three agents have been approved in the US and Europe for multiple indications, where they have shown promising efficacy.

Third-generation agents are emerging. These are a broader set, targeting other aspects of the immune system. They promise multiple therapeutic options that can be tailored to the patient and offer a wide range of possibilities for combination (Hoos et al, 2016).
 

Download the full article from Blue Latitude Health

7th July 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom

Latest content on this profile

Building a creative marketing consultancy: how we’ve transitioned into a full service global team
In this Q&A, James Atherton, Vice President and Managing Consultant at our New York office, reveals how our NYC and London offices work together and why having a creative services capability has changed the way we deliver strategic work for clients.
Blue Latitude Health
Creative effectiveness: how to achieve tangible results
Chris Field, Director and Head of Creative Services at Blue Latitude Health, reveals what it takes to create winning creative campaigns that achieve results in the Pharma market.
Blue Latitude Health
How to build an online medical information service that resonates with your customers
Sourcing medical information is a top challenge for healthcare professionals in 2017. Here, Blue Latitude Health Associate Consultant Jiayi Chen gives you the inside scoop on how to build a digital service that really serves the needs of your customers.
Blue Latitude Health
Could ketamine be the next big thing in depression?
Account Executive Will Frostick discusses the established treatment model for depression and its limitations, as well as a new entrant poised to revolutionise the field – ketamine.
Blue Latitude Health
Creativity in a complex landscape: a pharma perspective
lue Latitude Health interviewed Mohamed Helal, Marketing Lead for Immunology IBVT at EMEA level for Janssen, to find out his view what an exceptional creative campaign looks like when working at the regional.
Blue Latitude Health
Creative effectiveness: international work that works
Creative Director Damien Parsonage explains how the creative department at Blue Latitude Health creates work that resonates with customers and delivers results.
Blue Latitude Health